Sulfasalazine maintains blood-brain barrier integrity and relieves lipopolysaccharide-induced inflammation in hCMEC/D3 cells

Abstract

Sulfasalazine is a recognized therapy for inflammatory bowel disease and is of paramount importance for maintaining intestinal barrier homeostasis. However, its effects on blood-brain barrier (BBB) function and inflammation have not yet been explored. We sought to examine whether sulfasalazine has anti-inflammatory and antiapoptotic effects on the BBB. hCMEC/D3 cells are a well-established BBB in vitro model, were treated with 1 μg/mL Escherichia coli O111:B4 lipopolysaccharide for 12 h. The cell counting kit-8 assay was used to assess cell viability. The cells were also treated with gradient concentrations of sulfasalazine for 12 h. The levels of apoptosis-related proteins and inflammatory factors (IL-1χ and TNF-α IL-6) were measured by western blotting. ZO-1 and F-actin expression was measured by immunofluorescence staining. This study confirmed that 5 mM sulfasalazine improved the maintenance of BBB integrity and relieved lipopolysaccharide-induced inflammatory apoptosis and showed that sulfasalazine might be an effective treatment for BBB disruption.